Loring Wolcott & Coolidge Fiduciary Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.4K	Hold	1,803	–	–	﹤0.01%	468
2026 Q1	$29.5K	Hold	1,803	–	–	﹤0.01%	458
2025 Q4	$27.9K	Hold	1,803	–	–	﹤0.01%	457
2025 Q3	$25.8K	Hold	1,803	–	–	﹤0.01%	465
2025 Q2	$11.6K	Hold	1,803	–	–	﹤0.01%	478
2025 Q1	$9.12K	Hold	1,803	–	–	﹤0.01%	487
2024 Q4	$6.29K	Hold	1,803	–	–	﹤0.01%	502
2024 Q3	$8.84K	Hold	1,803	–	–	﹤0.01%	503
2024 Q2	$4.25K	Hold	1,803	–	–	﹤0.01%	523
2024 Q1	$3.57K	Hold	1,803	–	–	﹤0.01%	539
2023 Q4	$28.8K	Hold	1,803	–	–	﹤0.01%	436
2023 Q3	$32.5K	Hold	1,803	–	–	﹤0.01%	454
2023 Q2	$38.9K	Buy	+1,803	New	+$48.7K	﹤0.01%	451
2022 Q4	–	Sell	-1,803	Closed	-$51K	–	577
2022 Q3	$51K	Buy	+1,803	New	+$45K	﹤0.01%	406

Other funds holding AMLX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

PPWP

Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's AMLX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 1,803 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #468.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in AMLX in Q3 2022 and has held it in 14 quarters since. The position peaked at $51K in Q3 2022. 27 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 1,803 shares of Amylyx Pharmaceuticals worth $32.4K as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #468 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Amylyx Pharmaceuticals position peaked at $51K in Q3 2022.
27 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.